Form 4: Halozyme CEO Exercises Options, Sells Shares

Halozyme Therapeutics CEO Helen Torley exercised stock options and subsequently sold common shares in pre-planned transactions.

Summary

• Helen Torley, President and CEO of Halozyme Therapeutics, Inc. (HALO), engaged in a series of stock option exercises and subsequent sales of common stock.
• The transactions occurred on February 3, 4, and 5, 2026, and were executed pursuant to a Rule 10b5-1 trading plan adopted on March 21, 2025.
• On February 3, 2026, 20,000 options were exercised at $12.07 per share, followed by sales of 2,551 shares at a weighted average price of $74.879, 9,659 shares at $75.944, and 7,790 shares at $76.734.
• On February 4, 2026, another 20,000 options were exercised at $12.07 per share, with subsequent sales of 9,900 shares at $76.936 and 10,100 shares at $77.54.
• On February 5, 2026, 10,000 options were exercised at $12.07 per share, and 5,376 shares were sold at $78.379, along with 4,624 shares at $78.936.
• The options exercised had a ten-year term expiring in February 2027 and were granted on February 22, 2017, exercisable over a 4-year period.
• Following these transactions, Helen Torley beneficially owns 708,719 shares of common stock and 201,923 derivative securities (options).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine insider transaction executed under a pre-established 10b5-1 plan, which typically has a neutral impact on market sentiment as it does not reflect new discretionary trading decisions based on material non-public information.

Positives

• The CEO is realizing significant value from previously granted stock options, with sales prices substantially higher than the exercise price of $12.07.
• The transactions were conducted under a Rule 10b5-1 trading plan, indicating pre-planned personal financial management rather than a discretionary sale based on new information.

Negatives

• The sale of common stock by a high-ranking insider, even if pre-planned, can sometimes be perceived negatively by some market participants.

Future Outlook

This Form 4 filing details past insider transactions and does not contain any forward-looking statements or guidance regarding the company's future outlook.

Management Comments

• The options exercised and sales reported were made pursuant to a written trading plan adopted by the Reporting Person on March 21, 2025, in accordance with Rule 10b5-1.
• The sales of common shares represent shares acquired following the exercise of stock options with a ten-year term expiring in February 2027.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those executed under a Rule 10b5-1 trading plan, are a common practice for corporate executives to manage personal finances, diversify their holdings, and provide liquidity without implying a change in their outlook on the company's prospects. Such pre-arranged plans are designed to avoid accusations of trading on material non-public information.

Stakeholder Impact

• Shareholders may observe the insider selling, but the execution under a Rule 10b5-1 plan generally mitigates concerns about the timing or motivation of the sales, suggesting personal financial planning rather than a lack of confidence in the company.

Key Dates

Recommendation

The transactions by CEO Helen Torley are routine exercises of stock options and subsequent sales of common stock, executed under a pre-established Rule 10b5-1 trading plan. This type of insider activity is generally considered neutral as it reflects personal financial planning rather than a discretionary market timing decision based on new material non-public information. Therefore, it does not provide a basis for a change in investment recommendation.

Keywords

Halozyme Therapeutics, HALO, Helen Torley, Insider Trading, Form 4, Stock Options, Share Sale, CEO Transaction, 10b5-1 Plan